A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules
Open Access
- 21 August 2025
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2026-2039
Abstract
Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches. In clinical studies, the gastric emptying delay (GED) was evaluated in healthy participants and patients with T2DM at various dose levels of dulaglutide. A PopPK model estimated the exposure‐dependent delay in gastric emptying, which was then input into the orally administered small molecule PBPK models. These PBPK models, informed by internal clinical studies and publicly available data, quantified the effect of dulaglutide‐induced GED on the area under the curve (AUC), maximum concentration ( C max ), and time to maximum concentration ( t max ) of the co‐administered drugs. The modeling approach was verified for reproducing observed GED‐mediated drug–drug interactions (DDIs) at low doses of dulaglutide and to predict DDIs at a 4.5 mg dulaglutide dose. The clinical studies demonstrated that the 1.5 mg dulaglutide dose has no clinically relevant effect on the pharmacokinetics of small molecules, and the modeling led to a similar conclusion at 4.5 mg dulaglutide. This work demonstrates that modeling approaches can be used to predict potential GLP‐1‐mediated DDIs related to gastric emptying delay, increasing the efficiency of the clinical pharmacology programs.Keywords
Funding Information
- Eli Lilly and Company
This publication has 41 references indexed in Scilit:
- Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product DevelopmentPharmaceutical Research, 2022
- Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platformsBiopharmaceutics & Drug Disposition, 2020
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsClinical Pharmacokinetics, 2015
- Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation MethodsJournal of Pharmaceutical Sciences, 2015
- Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetesThe Journal of Clinical Pharmacology, 2015
- From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case exampleBiopharmaceutics & Drug Disposition, 2012
- The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophenAdvances in Therapy, 2011
- Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteersBiopharmaceutics & Drug Disposition, 2007
- Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteersBiopharmaceutics & Drug Disposition, 2007
- Intestinal Absorption Mechanism of Dipeptide Angiotensin Converting Enzyme Inhibitors of the Lysyl-Proline Type: Lisinopril and SQ 29,852Journal of Pharmaceutical Sciences, 1989